This collection of case studies is designed to illustrate challenging and controversial aspects of perioperative medicine. The authors guide readers through four case narratives punctuated by practical multiple-choice questions followed by the authors' commentary on the evidence supporting various answer choices and related considerations. The objective is to examine issues and key evidence that should inform the decision-making process in important aspects of perioperative management. Dr. Steven L. Cohn: The latest edition of the American College of Chest Physicians (ACCP) evidence-based guidelines on antithrombotic therapy recommends the use of therapeutic-dose subcutaneous LMWH over IV UFH for initial treatment of acute DVT in the outpatient or inpatient setting. 1 Additionally, indications for an IVC fi lter include the prevention of pulmonary embolism (PE) in a patient with DVT who requires full-dose anticoagulation but cannot receive it, as would be the case here if the patient proceeds with surgery as scheduled. So if surgery will be postponed, the best option is LMWH; if surgery will not be postponed, the best answer is a combination of pharmacologic therapy with low-dose LMWH and an IVC fi lter, preferably a retrievable one. 3 Therefore, I would suggest that the patient wait at least 1 month after an acute DVT before undergoing surgery.
the patient was at high risk for a PE. Even though the documented risk of postponing radical prostatectomy for a short time is inconsequential, I was convinced that the patient would not believe this if metastasis were to develop in the future. 
Question 1.4:

Dr. Cohn:
The correct timing for stopping LMWH is 24 hours before surgery. As for how to resume anticoagulation in patients at high risk for VTE or those undergoing major surgery, the latest ACCP guidelines recommend the following 4 : • Reinitiation of anticoagulation 12 to 24 hours postoperatively, assuming adequate hemostasis in patients not at high risk for bleeding
• Use of a prophylactic dose or no anticoagulation for up to 72 hours if the patient is at high risk for bleeding.
These recommendations are a departure from previous practice, in which we routinely restarted anticoagulation 6 to 12 hours postoperatively.
Dr. Sweitzer:
According to guidelines from the American Society of Regional Anesthesia and Pain Medicine (ASRA), 5 if twice-daily LMWH is stopped 24 hours ahead of time (as long as patients have normal renal function), it is safe to perform epidural or spinal anesthesia, if either is an option. If full-dose UFH is used, the partial thrombo plastin time (PTT) is monitored and central neuraxial blockade may be done if the PTT is in the normal range, which typically is 2 to 6 hours after UFH is stopped.
Additionally, the platelet count should be checked every 3 days postoperatively while the patient is on UFH or LMWH. It may be just as important to monitor the platelet count preoperatively if the patient has been on UFH or LMWH for an extended duration, especially if a central neuraxial anesthetic technique is planned.
Dr. Cohn:
The reason for monitoring the platelet count is the potential for heparin-induced thrombocytopenia in patients on UFH. I recently encountered a patient who developed postoperative heparin-induced thrombocytopenia with thrombosis while on LMWH, which is relatively uncommon compared with UFH. Dr. Sweitzer: I would push up the metoprolol a bit to reduce the heart rate, knowing that beta-blockers are probably not the most effi cacious antihypertensive agents. I would caution against starting an angiotensinconverting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) because he is scheduled to undergo a fairly signifi cant procedure with expected blood loss and fl uid shifts, and either of those agents in combination with a beta-blocker would be challenging to manage on the day of surgery.
Case resolution
Question 2.3: How would you manage his metformin perioperatively? A. Discontinue it 48 hours preoperatively B. Discontinue it 24 hours preoperatively C. Withhold it on the morning of surgery D. Continue it on the morning of surgery
Dr. Sweitzer: We routinely advise patients to hold all their oral diabetes medications the morning of surgery, primarily because many anesthesiologists are uncertain about the differing risks of hypoglycemia associated with the various oral agents.
Most of us will never see a patient who has lactic acidosis from metformin use. A systematic literature review and analysis found no increase in the risk of lactic acidosis with metformin compared with other oral hypoglycemics, 6 so fear of lactic acidosis is not a valid reason to discontinue metformin. In fact, I think it is inappropriate to ever postpone or cancel surgery simply because the patient inadvertently took metformin on the morning of surgery. Some may argue that patients with renal insuffi ciency are at higher risk of lactic acidosis from metformin use on the morning of surgery, but keep in mind that renal insuffi ciency is a relative contraindication to metformin use in the fi rst place. Unless the patient is scheduled for a bilateral nephrectomy, his or her renal function is not going to be acutely reduced enough to enable a morning dose of metformin to cause lactic acidosis.
Dr. Cohn:
Additionally, in a recent study of patients undergoing coronary artery bypass graft surgery (CABG), there was no increased risk of in-hospital morbidity or mortality in patients who received metformin on the morning of surgery, 7 although I typically stop it 24 hours before major surgery. The reason not to start a prophylactic statin would be the lack of evidence of benefi t in patients undergoing noncardiac, nonvascular surgery, although there is evidence of potential benefi t in patients undergoing vascular surgery. * The arguments in favor of starting a statin are that this patient has independent indications for a statin and the planned surgery is a high-risk procedure.
In cohort studies, perioperative death rates have been lower in statin recipients than in those not taking a statin. 8 In the Dutch Echographic Cardiac Risk Evaluation Applying Stress Echo III (DECREASE III), which randomized noncardiac vascular surgery patients to perioperative fl uvastatin or placebo, rates of MI and the composite end point of nonfatal MI or cardiovascular death were signifi cantly lower in the statin group than in the placebo group. 10 The guidelines' recommendation is to delay surgery for further evaluation and treatment. He is already on maximal medical therapy, which has failed to control his symptoms. He has poor exercise capacity. The only difference among the case scenarios is a variation in surgical risk.
This patient has independent indications for coronary angiography regardless of whether or not he's undergoing surgery. He deserves evaluation for possible revascularization to improve his quality of life and symptoms.
I would send the patient to the catheterization lab in every one of these instances, with the possible exception of the cystoscopy scenario, where one could argue that revascularization with stenting would require antiplatelet therapy that might increase the bleeding risk, and also that the antiplatelet therapy would have to be interrupted for the cystoscopy, potentially increasing thrombotic risk.
Dr. Sweitzer: I disagree. The ACC/AHA 2007 guidelines do not recommend going directly to catheterization but rather recommend delaying surgery for further evaluation and treatment. 10 We must ask whether this patient is truly receiving optimal medical management. After all, he is not on an ACE inhibitor or an ARB.
We must also consider whether the surgery is truly elective. In the fi rst scenario, if he has peripheral vascular disease, he is likely to develop gangrene and have a further decrease in exercise capacity, which reduces his functional ability and increases his risk of comorbid conditions. He is at signifi cant risk of developing worsening renal insuffi ciency or renal failure if he undergoes angiography. Coronary revascularization will delay treatment of his peripheral vascular disease. The Coronary Artery Revascularization Prophylaxis (CARP) trial showed no benefi t of coronary revascularization relative to medical management in patients undergoing vascular surgery, 11 as is planned for this patient. I believe one must balance two competing risks and have an in-depth discussion with the patient.
In the second scenario, not treating gallstones or preventing cholelithiasis poses more risk to the health of this diabetic patient than does elective surgery if he needs a cholecystectomy. Emergency surgery, especially for acute cholecystitis, also signifi cantly increases the risk of a cardiac event.
In the third scenario, the cystoscopy may uncover bladder cancer, which may be adversely affected by a delay of surgery. Regardless, the patient had gross hematuria and would be at risk for further bleeding should he undergo stenting with the requisite antiplatelet therapy.
Catheterization is not normally recommended unless CABG or stenting is being considered, yet I have seen no data that either of these procedures prolongs life except in very limited circumstances such as left main disease treated with bypass grafting. Though it is true that CABG reduces the incidence and severity of angina, it does not modify the physiologic cause of angina but rather may result in symptom improvement by damaging somatic nerve fi bers to the heart. Putting a stent in this patient would be like applying a bandage: his symptoms will likely recur if he does not receive optimal medical management.
In a 2007 science advisory, several major medical societies cautioned against percutaneous coronary intervention (PCI) with drug-eluting stent placement in patients expected to undergo noncardiac surgery that would require interruption of antiplatelet therapy in the following 12 months (and against PCI with bare metal stent placement in patients undergoing such surgery in the following 4 to 6 weeks). 12 Therefore, I would not recommend catheterization for a patient whose noncardiac disease is likely to require surgery in the very near future, as is the case in each of the surgical scenarios above. One could consider noninvasive stress testing, which would be a safer approach and would almost certainly identify either signifi cant stenosis of the left main coronary artery or three-vessel disease, which would be the only possible reasons to recommend CABG. I don't believe there is any role for PCI for this patient.
Dr. Cohn: I argue for symptom relief even if it doesn't prolong life. This patient cannot walk across the room without having symptoms despite taking multiple medications. I think he deserves a chance at revascularization if the angiogram shows he has a stenosis amenable to it, but I agree that a drug-eluting stent should not be placed if we know that he will undergo surgery within a few months. Dr. Cohn: This is not a case of lupus anticoagulant because the abnormal PTT was corrected by the mixing study. Causes of a prolonged PTT include defi ciencies of factors XII, XI, and IX, so factor XII defi ciency is the most likely explanation, though a defi ciency higher up the coagulation cascade (ie, prekallikrein factor deficiency) is possible. In the absence of any personal or family bleeding history, it is unlikely to be a defi ciency of factors VII or IX (the hemophiliac) or of factor XI, so a defi ciency of factor XII or one of the prekallikrein factors is more likely.
   CASE 4: VENTRAL HERNIA REPAIR IN A MIDDLE-AGED WOMAN
Dr. Sweitzer:
A mixing study is indeed the appropriate fi rst step. It is ordered from the lab and involves mixing the patient's blood with normal plasma and incubating the mixture. If the mixture corrects the PTT result, as was the case with this patient, it indicates a coagulation factor defi ciency in the patient's blood; if it doesn't correct, that should prompt evaluation for lupus anticoagulant or the presence of some other protein or hormone that's prolonging the PTT. Factor XI defi ciency is associated with bleeding, but usually there is a family history or a personal history of bleeding with surgery.
Screening coagulation studies are not usually indicated in a patient without a personal or family history of bleeding, liver disease, alcohol or drug use, or current anticoagulant therapy. Such studies are usually normal in such patients, and when they are not, it's usually because of a lab error or a disease (hypercoagulable state) or factor defi ciency that does not cause bleeding Dr. Sweitzer: However, if the PTT is prolonged, the cause should be identifi ed, because if the patient is sent to the operating room without an explanation for the prolongation, the perioperative team might think the patient has a bleeding problem and use fresh frozen plasma too readily. Fresh frozen plasma is not appropriate for everyone and may actually make a potentially hypercoagulable state worse.
  DISCUSSION
Question from the audience: It was said that use of ACE inhibitors and ARBs should be avoided around the time of surgery. I've done an extensive literature search and found minimal to no evidence to support this practice. To the contrary, I found fairly good evidence to indicate that heart failure can be exacerbated signifi cantly and acutely, as early as within 24 hours, when patients are taken off their ACE inhibitor or ARB. I would like your viewpoint on this basic pathology in perioperative medicine.
Dr. Cohn:
The literature on the use of ACE inhibitors or ARBs prior to noncardiac surgery consists of fi ve studies with fewer than 500 patients in total, as recently reviewed by Rosenman et al. 13 Although there was no excess of death or MI associated with taking these medications on the morning of surgery, they did increase the need for fl uid and pressors.
Dr. Sweitzer: Patients with hypertension have bigger variations of blood pressure, both hypo-and hypertension, in the perioperative period. For this reason, it was standard of care 30 years ago to stop all antihypertensive drugs, including beta-blockers, preoperatively. We soon found that although this practice prevented many episodes of hypotension, it increased the occurrence of perioperative hypertension and the likelihood of cardiac events. It then became standard of care to always continue antihypertensive drugs on the morning of surgery. In the late 1980s and early 1990s, several studies showed that ACE inhibitors and ARBs were associated with a more profound drop in blood pressure upon induction of general anesthesia compared with other antihypertensives.
The usual ways we treat drops in blood pressure-with phenylephrine and ephedrine-are not very effective in treating hypotension associated with general anesthesia in patients taking ACE inhibitors or ARBs. Vasopressin is effective in treating refractory hypotension during surgery, but anesthesiologists don't use it often. Reducing the doses of induction agents is another means of attenuating the hypotension induced by ACE inhibitors and ARBs.
We should not routinely stop ACE inhibitors and ARBs on the day of surgery, particularly in patients being treated for heart failure, angina, or a prior MI. My bias is to selectively hold ACE inhibitors and ARBs on the morning of surgery in patients who are undergoing a signifi cant operation with a high likelihood of hypotension, have well-controlled preoperative blood pressure, are taking multiple antihypertensive agents, and do not
